ESC Congress 2025 - FARADISE Registry finds FARAPULSE™ pulsed field ablation (PFA) system safe and easy to use, with an 80% clinical effectiveness at one year in paroxysmal AF.
Prof Lucas Boersma (St Antonius Hospital, Nieuwegein, NL) joins us to discuss one-year findings from the observational, prospective, single-arm FARADISE global registry (NCT05501873) which collected real-world data from up to 100 sites in Europe to investigate the clinical effectiveness of the FARAPULSE™ Pentaspline PFA system.
The registry found that the PFA system was safe and easy to use, with a low event rate of 1.5% at one year. In terms of effectiveness, at one year clinical effectiveness is around 80% for paroxysmal AF, and around 70% for persistent AF.
Interview Questions:
1. What is the reasoning behind the FARADISE global registry?
2. Could you tell us about the unique features of the FARAPULSE™ PFA system?
3. What was the study design and patient population?
4. What are the key findings?
5. What are the take-home messages for practice, and what are the next steps?
Recorded on-site at ESC Congress 2025, Madrid.
Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Arrhythmia Academy.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Prof Lucas Boersma (St Antonius Hospital, Nieuwegein, NL) joins us to discuss one-year findings from the observational, prospective, single-arm FARADISE global registry (NCT05501873) which collected real-world data from up to 100 sites in Europe to investigate the clinical effectiveness of the FARAPULSE™ Pentaspline PFA system.
The registry found that the PFA system was safe and easy to use, with a low event rate of 1.5% at one year. In terms of effectiveness, at one year clinical effectiveness is around 80% for paroxysmal AF, and around 70% for persistent AF.
Interview Questions:
1. What is the reasoning behind the FARADISE global registry?
2. Could you tell us about the unique features of the FARAPULSE™ PFA system?
3. What was the study design and patient population?
4. What are the key findings?
5. What are the take-home messages for practice, and what are the next steps?
Recorded on-site at ESC Congress 2025, Madrid.
Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Arrhythmia Academy.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
- Categoria
- Cardiology
Commenta per primo questo video.









